Tricyclic compounds of the general Formula I: ##STR1## as defined herein which exhibit antagonist activity at V.sub.1 and/or V.sub.2 receptors and exhibit in vivo vasopressin antagonist activity, methods for using such compounds in treating diseases characterized by excess renal reabsorption of water, and processes for preparing such compounds.
Pyridobenzoxazepine and pyridobenzothiazepine vasopressin antagonists
申请人:American Cyanamid Company
公开号:US05686445A1
公开(公告)日:1997-11-11
Tricyclic compounds of the general Formula I: ##STR1## as defined herein which exhibit antagonist activity at V.sub.1 and/or V.sub.2 receptors and exhibit in vivo vasopressin antagonist activity, methods for using such compounds in treating diseases characterized by excess renal reabsorption of water, and processes for preparing such compounds.
N-acylated tricyclic azaheterorings useful as vasopressin antagonists
申请人:American Cyanamid Company
公开号:EP0640592B1
公开(公告)日:1998-12-30
[EN] TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS<br/>[FR] COMPOSES TRICYCLIQUES DE BENZAZEPINE ANTAGONISTES DE LA VASOPRESSINE
申请人:AMERICAN CYANAMID COMPANY
公开号:WO1997047624A1
公开(公告)日:1997-12-18
(EN) Tricyclic compounds of general formula (I), particularly those wherein Y is a bond, A-B is -(CH2)2-NR3- or -NR3-(CH2)2- and the moiety (II) represents an optionally substituted fused pyrazole ring, exhibit vasopressin antagonist activity and are useful in treating diseases characterized by excess renal reabsorption of water.(FR) Cette invention se rapporte à des composés tricycliques représentés par la formule (I) et notamment à des composés dans lesquels Y est une liaison, A-B est -(CH2)2-NR3- ou -NR3-(CH2)2- et la fraction (II) représente un noyau pyrazole condensé éventuellement substitué. Lesdits composés tricycliques présentent une activité antagoniste dirigée contre la vasopressine et ils servent à traiter des maladies caractérisées par une réabsorption rénale excessive d'eau.
Tricyclic benzazepine vasopressin antagonists
申请人:American Cyanamid Company
公开号:US05512563A1
公开(公告)日:1996-04-30
Tricyclic compounds of the general Formula I: ##STR1## as defined herein which exhibit antagonist activity at V.sub.1 and/or V.sub.2 receptors and exhibit in vivo vasopressin antagonist activity, methods for using such compounds in treating diseases characterized by excess renal reabsorption of water, and processes for preparing such compounds.